F S&P 500
5,203.00 -9.75 (-0.19%) F Dow Jones
39,144.00 -51.00 (-0.13%) F Nasdaq
18,137.00 -49.50 (-0.27%) E-mini Russell 2000 Index Futur
2,056.80 -8.00 (-0.39%) Petróleo
79.67 +0.68 (+0.86%) Oro
2,319.70 -2.60 (-0.11%)
Verrica Pharmaceuticals Inc. (VRCA)
Fuera de horario:
Verrica Pharmaceuticals Inc.
44 West Gay Street
Suite 400
West Chester, PA 19380
United States
484 453 3300
https://www.verrica.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 100
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Ted White | President, CEO & Director | 914.68k | N/D | 1965 |
| Mr. Christopher G. Hayes | Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel | 607.38k | N/D | 1964 |
| Mr. Joe Bonaccorso | Chief Commercial Officer | 635.38k | N/D | 1964 |
| Mr. P. Terence Kohler | Chief Financial Officer | N/D | N/D | N/D |
| Dr. Gary Goldenberg M.D. | Chief Medical Officer | 553.03k | N/D | 1977 |
| Mr. Eugene Scavola | Executive Vice President of Technical Operations | N/D | N/D | N/D |
| Dr. Bradley J. Catalone MBA, Ph.D. | Head of Drug Development | N/D | N/D | N/D |
Descripción
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Verrica Pharmaceuticals Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 10; Derechos del accionista: 8; Compensación: 8.
